168 related articles for article (PubMed ID: 15650021)
1. The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions.
Pascual-Le Tallec L; Simone F; Viengchareun S; Meduri G; Thirman MJ; Lombès M
Mol Endocrinol; 2005 May; 19(5):1158-69. PubMed ID: 15650021
[TBL] [Abstract][Full Text] [Related]
2. Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53.
Shinobu N; Maeda T; Aso T; Ito T; Kondo T; Koike K; Hatakeyama M
J Biol Chem; 1999 Jun; 274(24):17003-10. PubMed ID: 10358050
[TBL] [Abstract][Full Text] [Related]
3. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.
DiMartino JF; Miller T; Ayton PM; Landewe T; Hess JL; Cleary ML; Shilatifard A
Blood; 2000 Dec; 96(12):3887-93. PubMed ID: 11090074
[TBL] [Abstract][Full Text] [Related]
4. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.
Luo RT; Lavau C; Du C; Simone F; Polak PE; Kawamata S; Thirman MJ
Mol Cell Biol; 2001 Aug; 21(16):5678-87. PubMed ID: 11463848
[TBL] [Abstract][Full Text] [Related]
5. Structure and function of RNA polymerase II elongation factor ELL. Identification of two overlapping ELL functional domains that govern its interaction with polymerase and the ternary elongation complex.
Shilatifard A; Haque D; Conaway RC; Conaway JW
J Biol Chem; 1997 Aug; 272(35):22355-63. PubMed ID: 9268387
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional inhibition of p53 by the MLL/MEN chimeric protein found in myeloid leukemia.
Maki K; Mitani K; Yamagata T; Kurokawa M; Kanda Y; Yazaki Y; Hirai H
Blood; 1999 May; 93(10):3216-24. PubMed ID: 10233872
[TBL] [Abstract][Full Text] [Related]
7. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia.
Thirman MJ; Levitan DA; Kobayashi H; Simon MC; Rowley JD
Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12110-4. PubMed ID: 7991593
[TBL] [Abstract][Full Text] [Related]
8. EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein.
Simone F; Polak PE; Kaberlein JJ; Luo RT; Levitan DA; Thirman MJ
Blood; 2001 Jul; 98(1):201-9. PubMed ID: 11418481
[TBL] [Abstract][Full Text] [Related]
9. ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties.
Simone F; Luo RT; Polak PE; Kaberlein JJ; Thirman MJ
Blood; 2003 Mar; 101(6):2355-62. PubMed ID: 12446457
[TBL] [Abstract][Full Text] [Related]
10. An RNA polymerase II elongation factor encoded by the human ELL gene.
Shilatifard A; Lane WS; Jackson KW; Conaway RC; Conaway JW
Science; 1996 Mar; 271(5257):1873-6. PubMed ID: 8596958
[TBL] [Abstract][Full Text] [Related]
11. ELL and EAF1 are Cajal body components that are disrupted in MLL-ELL leukemia.
Polak PE; Simone F; Kaberlein JJ; Luo RT; Thirman MJ
Mol Biol Cell; 2003 Apr; 14(4):1517-28. PubMed ID: 12686606
[TBL] [Abstract][Full Text] [Related]
12. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice.
Lavau C; Luo RT; Du C; Thirman MJ
Proc Natl Acad Sci U S A; 2000 Sep; 97(20):10984-9. PubMed ID: 10995463
[TBL] [Abstract][Full Text] [Related]
13. Identification and purification of the Holo-ELL complex. Evidence for the presence of ELL-associated proteins that suppress the transcriptional inhibitory activity of ELL.
Shilatifard A
J Biol Chem; 1998 May; 273(18):11212-7. PubMed ID: 9556611
[TBL] [Abstract][Full Text] [Related]
14. ELL-associated factors 1 and 2 are positive regulators of RNA polymerase II elongation factor ELL.
Kong SE; Banks CA; Shilatifard A; Conaway JW; Conaway RC
Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10094-8. PubMed ID: 16006523
[TBL] [Abstract][Full Text] [Related]
15. ELL inhibits E2F1 transcriptional activity by enhancing E2F1 deacetylation via recruitment of histone deacetylase 1.
Zhang W; Ji W; Liu X; Ouyang G; Xiao W
Mol Cell Biol; 2014 Feb; 34(4):765-75. PubMed ID: 24344198
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the MEN/ELL protein, an RNA polymerase II elongation factor, results in transformation of Rat1 cells with dependence on the lysine-rich region.
Kanda Y; Mitani K; Kurokawa M; Yamagata T; Yazaki Y; Hirai H
J Biol Chem; 1998 Feb; 273(9):5248-52. PubMed ID: 9478981
[TBL] [Abstract][Full Text] [Related]
17. Sequence, structural and functional conservation among the human and fission yeast ELL and EAF transcription elongation factors.
Sweta K; Dabas P; Sharma N
Mol Biol Rep; 2022 Feb; 49(2):1303-1320. PubMed ID: 34807377
[TBL] [Abstract][Full Text] [Related]
18. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.
So CW; Cleary ML
Mol Cell Biol; 2002 Sep; 22(18):6542-52. PubMed ID: 12192052
[TBL] [Abstract][Full Text] [Related]
19. The amino-terminal domain of ELL transcription elongation factor is essential for ELL function in Schizosaccharomyces pombe.
Sweta K; Dabas P; Jain K; Sharma N
Microbiology (Reading); 2017 Nov; 163(11):1641-1653. PubMed ID: 29043956
[TBL] [Abstract][Full Text] [Related]
20. Elongation factor ELL (Eleven-Nineteen Lysine-rich Leukemia) acts as a transcription factor for direct thrombospondin-1 regulation.
Zhou J; Feng X; Ban B; Liu J; Wang Z; Xiao W
J Biol Chem; 2009 Jul; 284(28):19142-52. PubMed ID: 19447890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
